4 unknown. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 4 |
Follow Leflunomide: new trials by email Literature Review of Leflunomide trials Research Report on Leflunomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations Leflunomide, The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab - RAS Mutation, Ras (Kras or Nras) Gene Mutation | Phase 2 | Unknown | N.N. Petrov National Medical Research Center of Oncology | 20 | 2023-10-03 | 2024-01-29 |
| Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor Leflunomide Pill - Neuroendocrine Tumors | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 50 | 2020-07-01 | 2024-08-07 |
| The Research of Standard Diagnosis and Treatment for HSPN in Children Prednisone, Cyclophosphamide(CTX), Mycophenolate mofetil(MMF) - Henoch-Schoenlein Purpura Nephritis | Phase 2 | Unknown | Nanjing Children's Hospital | 100 | 2015-08-01 | 2020-02-26 |
| Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid leflunomide - Bullous Pemphigoid | Phase 2 | Unknown | University Hospital, Limoges | 54 | 2007-09-01 | 2008-12-04 |
Colorectal Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Multiple Endocrine Neoplasia (1) · Neoplasms (1) · Neuroendocrine Tumors (1) · Pancreatic Neoplasms (1) · Pemphigoid, Bullous (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · N.N. Petrov National Medical Research Center of Oncology (1) · Nanjing Children's Hospital (1) · University Hospital, Limoges (1)
China (2) · France (1) · Russia (1)
Aihua Zhang, M.D. (1) · Evgeny Imyanitov (1) · Hong Zhao (1)